13 results about "Alcohol use disorder" patented technology

The invention relates to application of an OIP5-AS1 gene in screening of alcohol use disorder, and belongs to the technical field of screening of alcohol use disorder. In order to solve the problem that an existing AUD screening method lacks a molecular marker related to genetic susceptibility and is difficult to realize early intervention and individualized prevention, the invention provides application of an OIP5-AS1 gene in alcohol use disorder screening, and particularly relates to application of the OIP5-AS1 gene in preparation of an alcohol use disorder screening kit. The OIP5-AS1 in a sample is amplified and detected through real-time fluorescent quantitative PCR (polymerase chain reaction) by taking plasma of a subject as a detection object, and if the relative expression quantity of the OIP5-AS1 gene reaches 1.53 threshold or above, the subject has genetic susceptibility to alcohol use disorder. The OIP5-AS1 gene as a marker can provide objective and quantifiable detection indexes, reflect individual genetic susceptibility and realize long-term risk prediction, and has important clinical application value.

The invention discloses application of putrescine as a molecular marker in preparation of a reagent for evaluating the severity of alcohol use disorder. The reagent is used for detecting the content of putrescine in a sample. By detecting the putrescine content in the excrement sample of the tested person, the alcohol use disorder severity of the person can be evaluated, and the method has important clinical significance for formulating a better diagnosis and treatment scheme.

A combination therapy for use in treatment of substance abuse disorders, including alcohol use disorder (AUD) and opioid use disorder (OUD), includes both mitragynine (MG) and naltrexone (NTX). NTX is understood to be a mu opioid antagonist that is expected to block MG's analgesic effects. However, combining MG and NTX therefore results in a unique, unexpected, and beneficial treatment that decreases alcohol self-administration to a greater extent than either alone.

Disclosed are method for predicting naltrexone response in subjects with AUD. In some embodiments, the methods include performing or having performed one or more methylation assays on a genomic DNA sample isolated from the subject to determine the methylation status of one or more regions of the isolated genomic DNA, wherein the one or more regions are subsequences of a gene selected from a mu opioid receptor (OPRM1) gene, a catechol-O-methyltransferase (COMT) gene, and a dopamine transporter (SLC6A3) gene, wherein the methylation status of the one or more regions of the isolated genomic DNA determined is predictive of naltrexone response in the subject. Also provided are method for treating patients diagnosed with AUD with the medication naltrexone based on a methylation status of a combination of specific methylation sites located associated with an OPRM1 gene, a COMT gene, and / or an SLC6A3 gene in obtained from each AUD patient.

This invention discloses a predictive model and its application for differentiating between alcohol use disorder (AUD) and alcoholic hepatitis (AH). By integrating the patient's basic clinical information, gut bacterial community characteristics, and gut fungal community structure, a multi-dimensional differentiation model is constructed. This model, through the joint analysis of gut microbiota (bacteria + fungi) and patient baseline data, provides an innovative and practical combination of molecular markers for the accurate differential diagnosis of AUD and AH.

The present invention relates to sulfamide derivatives of formula I, wherein the meaning of groups R1 and R2 is indicated in the description, for use to prevent and / or treat alcohol use disorder. The invention also relates to the administration of these derivatives in combination with other drugs and / or ligands. (I)

The disclosure provides a treatment for alcohol use disorder and related acetaldehyde toxicity, comprising repleting intracellular NAD+, and which may further comprise the administration of a GLP- 1 or dual GLP-1 / GIP receptor against.

The disclosure is directed to, in part, compounds, or pharmaceutically acceptable salts or solvates thereof, for modulating the activity of aldehyde dehydrogenase such as ALDH2 and / or methods for treating and / or preventing an alcohol related disorder such as alcohol use disorder, alcohol induced disorder, alcohol abuse, alcohol dependence, alcohol intoxication, alcohol withdrawal, and the like and / or methods for reducing the amount of alcohol consumed, reducing alcoholic cravings, or increasing the percentage of no heavy drinking days for a subject with alcohol use disorder.

This disclosure relates to methods for treating alcohol use disorder by administering to a human subject in need a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof. In certain embodiments, the compound is a compound of formula (II), (IIA), (IIB), or (IIC), or a solvate thereof, and is administered in a dose of from about 0.10 mg to about 10.0 mg. The disclosure also provides methods of preventing relapse to alcohol drinking, for reducing alcohol consumption, for decreasing alcohol craving, for maintenance of alcohol abstinence, for treating or preventing withdrawal from alcohol consumption, treating alcohol-related sleep disorder, and / or for reducing stress or anxiety level in a human subject.

The invention features methods for using 5-methoxy-N,N-dimethyltryptamine (5'MeO-DMT) in the treatment of substance use disorders (SUD), including specifically alcohol use disorder (AUD). Provided are specific therapeutically effective doses of 5-MeO-DMT which are well tolerated by patients and sufficient to induce a clinical response in the patient.

The invention relates to the technical field of medical information processing and health behavior intervention, and discloses an alcohol use disorder rehabilitation data processing system and method. A physiological monitoring terminal is deployed in the system, heart rate variability, galvanic conductance and skin temperature in a resting state are imported, and two-point calibration is performed to obtain an individual baseline; high-risk points are recorded, fences are arranged, and entering and exiting are judged according to the spherical distance; three parameters are collected regularly, channel availability and sample effectiveness are judged according to medical upper and lower limit normalization, and real-time deviation is calculated; summarizing according to natural days to generate a next-day individualized threshold value; when entering the fence and deviating from the over threshold, triggering the risk, calculating the intensity and performing four-stage grading; implementing micro intervention according to grades and recording; after intervention, a fixed window is used for re-measurement, and deviation, improvement and summarization are obtained; and performing seven-day statistical triggering and risk, aggregating daily average deviation and daily improvement, and generating a training duration and period report.

The disclosure relates to the field of alcohol use disorder. The disclosure provides methods of treating a subject having alcohol use disorder that includes administering ondansetron to a subject having a specified genotype corresponding to genetic variants that effect the 5-HT3 receptor complexes to which ondansetron binds and / or genetic variants that effect the expression of the serotonin transporter.

Disclosed are agents, compositions, and methods including valeric acid, or a pharmaceutically acceptable salt thereof or a derivative thereof, for treating or preventing alcohol use disorder or alcohol risk consumption.